Inventiva S.a. income statement

In fiscal 2025, Inventiva S.a. reported revenue of $5.1m, down 49.1% on the year before, operating income of −$159m (a -3145.5% margin) and net income of −$400m, or −$2.15 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Inventiva S.a.: income statement, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	4	8	0	5	13	19	10	5
Research and development	38	38	27	57	64	119	98	98
Operating income	−39	−34	−34	−62	−60	−111	−106	−159
Interest expense	0	0	0	0	1	6	13	38
Income tax	—	0	0	0	−0	1	0	0
Net income	−39	−34	−38	−59	−57	−119	−199	−400
Diluted EPS	—	−$0.48	−$0.38	−$0.50	−$0.46	−$0.88	−$1.11	−$2.15
Diluted shares (average)	62m	71m	102m	118m	124m	136m	179m	187m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ANL vs IVA IMRN vs IVA IVA vs RANI

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inventiva S.a.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inventiva S.a.